Replimune Files 8-K for Rule 425 Communications

Ticker: REPL · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1737953

Replimune Group, Inc. 8-K Filing Summary
FieldDetail
CompanyReplimune Group, Inc. (REPL)
Form Type8-K
Filed DateJan 8, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $466 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: corporate-action, regulatory-filing, securities-offering

TL;DR

**REPL just filed an 8-K for Rule 425 communications, signaling potential M&A or offering activity.**

AI Summary

Replimune Group, Inc. filed an 8-K on January 8, 2024, to disclose that it is making written communications pursuant to Rule 425 under the Securities Act. This filing indicates that the company is actively engaging in communications that could be related to a business combination or offering, which is important for investors because it suggests potential strategic activities that could impact the stock's future value and direction.

Why It Matters

This filing signals that Replimune is likely involved in activities like a merger, acquisition, or a new stock offering, which could significantly affect its financial structure and stock price.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying event it signals (potential M&A or offering) carries inherent risks and opportunities for investors.

Analyst Insight

A smart investor would monitor Replimune's subsequent filings and press releases closely for specific details regarding the nature of the Rule 425 communications, as this could signal significant corporate actions.

Key Players & Entities

  • Replimune Group, Inc. (company) — the registrant filing the 8-K
  • January 8, 2024 (date) — date of earliest event reported
  • Rule 425 (other) — SEC rule governing written communications related to business combinations or offerings
  • Securities Act (other) — act under which Rule 425 falls
  • 001-38596 (other) — Commission File Number for Replimune Group, Inc.
  • REPL (other) — trading symbol for Replimune Group, Inc.
  • Nasdaq Global Select Market (other) — exchange where Replimune's common stock is registered

Forward-Looking Statements

  • Replimune Group, Inc. will announce details of a business combination or a new offering. (Replimune Group, Inc.) — medium confidence, target: Q1 2024

FAQ

What is the primary purpose of Replimune Group, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of Replimune Group, Inc.'s 8-K filing on January 8, 2024, is to indicate that the registrant is making written communications pursuant to Rule 425 under the Securities Act.

What does checking the box for 'Written communications pursuant to Rule 425 under the Securities Act' imply for Replimune?

Checking this box implies that Replimune is engaging in communications that are typically associated with business combinations (like mergers or acquisitions) or certain types of public offerings, which require specific disclosure under SEC rules.

What is Replimune Group, Inc.'s trading symbol and on which exchange is its common stock registered?

Replimune Group, Inc.'s trading symbol is REPL, and its common stock is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).

What is the business address and phone number of Replimune Group, Inc. as stated in the filing?

The business address of Replimune Group, Inc. is 500 Unicorn Park Drive Suite 303, Woburn, MA 01801, and its telephone number is (781) 222-9600.

What is the Commission File Number for Replimune Group, Inc.?

The Commission File Number for Replimune Group, Inc. is 001-38596.

Filing Stats: 850 words · 3 min read · ~3 pages · Grade level 12.8 · Accepted 2024-01-08 08:00:37

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
  • $466 million — December 31, 2023, it had approximately $466 million in cash and cash equivalents and short-

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Replimune Group, Inc. (the "Company") announced updated clinical data of RP1 and RP2 during a presentation at the 42 nd Annual J.P. Morgan Healthcare Conference. A copy of the presentation slides are furnished as Exhibit 99.1 to this Current Report on Form 8-K and a replay of the webcast will be available on the Company's website at www.replimune.com under "Investors and Media" for 30 days following the event. The Company undertakes no obligation to update, supplement or amend the materials attached hereto. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

01 Other Events

Item 8.01 Other Events. The Company preliminarily estimates that as of December 31, 2023, it had approximately $466 million in cash and cash equivalents and short-term investments. The Company believes that its existing cash and cash equivalents and short-term investments along with its debt commitments will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2026. This amount is unaudited and preliminary, and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2023. The review of the Company's condensed consolidated financial statements for the three and nine-months ended December 31, 2023 is ongoing and could result in changes to the preliminary estimates due to the completion of financial closing procedures, final adjustments and other developments that may arise between now and the time the condensed consolidated financial statements the three and nine-months ended December 31, 2023 are finalized and publicly released. The Company's independent registered public accounting firm, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary financial estimate, and does not express an opinion or any other form of assurance with respect thereto. The preliminary financial estimate presented above has been prepared by and is the responsibility of management. Estimates of financial results are inherently uncertain and subject to change, and the Company undertakes no obligation to update this information. In addition, the estimated balance of cash and cash equivalents and short-term investments as of December 31, 2023 is not necessarily indicative of future performance or any other period, including the results to be achieved for the remainder of the fiscal year ending March 31, 2024 or any future period.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Company Presentation dated January 8, 2024 104 Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: January 8, 2024 By: /s/ Philip Astley-Sparke Philip Astley-Sparke Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.